Literature DB >> 10427942

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma.

G Cohn-Cedermark1, E Månsson-Brahme, L E Rutqvist, O Larsson, T Singnomklao, U Ringborg.   

Abstract

The objective of this population-based study was to assess metastatic pathways and outcomes vs. selected clinical and histopathologic features of the primary tumor in patients with recurrent cutaneous malignant melanoma. At a median follow-up time of 11 years, 569/2493 patients with recurrence were identified. We demonstrated a 5-year survival rate of 82% and 30% among those with a primary local or regional recurrence, respectively. Patients with primary distant skin, distant lymph node, or pulmonary metastases had a significantly better survival compared with those with CNS, bone, visceral, liver, or multiple sites of first distant metastases. The metastatic pathways were similar with regard to histogenetic type, primary tumor thickness, Clark's level of invasion, and primary tumor ulceration. Different histogenetic types, as assessed by light microscopy, imply different risks of recurrence. However, once the recurrence is manifest, the metastatic pathways are uniform, as well as prognosis, and survival.

Entities:  

Mesh:

Year:  1999        PMID: 10427942     DOI: 10.1080/028418699431122

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  16 in total

1.  Sentinel bruising as a presentation of metastatic melanoma.

Authors:  Lloyd Steele; Chit Cheng Yeoh
Journal:  BMJ Case Rep       Date:  2019-02-25

2.  Laparoscopic liver resection for metastatic melanoma.

Authors:  Davit L Aghayan; Airazat M Kazaryan; Åsmund Avdem Fretland; Mushegh A Sahakyan; Bård I Røsok; Bjørn Atle Bjørnbeth; Bjørn Edwin
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

3.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

4.  Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Authors:  Anaïs Vallet; Bastien Oriano; Laurent Mortier; Stéphane Dalle; Caroline Dutriaux; Bernard Guillot; Marie-Thérèse Leccia; Sophie Dalac; Philippe Saiag; Jean-Philippe Lacour; Delphine Legoupil; Julie De Quatrebarbes; Florence Brunet-Possenti; Thierry Lesimple; Jean-Philippe Arnault; François Aubin; Florence Granel-Brocard; Pierre-Emmanuel Stoebner; Eve Maubec; Brigitte Dreno; Clara Allayous; Raphaël Porcher; Céleste Lebbé
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

5.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

6.  Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.

Authors:  Shun-Da Du; Yi-Lei Mao; Shao-Hua Li; Xin-Ting Sang; Xin Lu; Yi-Yao Xu; Hai-Feng Xu; Lin Zhao; Chun-Mei Bai; Shou-Xian Zhong; Jie-Fu Huang
Journal:  World J Hepatol       Date:  2012-11-27

7.  A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis.

Authors:  Harald F Langer; Valeria V Orlova; Changping Xie; Sunil Kaul; Darius Schneider; Anke S Lonsdorf; Manuela Fahrleitner; Eun Young Choi; Vanessa Dutoit; Manuela Pellegrini; Sylvia Grossklaus; Peter P Nawroth; Gustavo Baretton; Sentot Santoso; Sam T Hwang; Bernd Arnold; Triantafyllos Chavakis
Journal:  Cancer Res       Date:  2011-05-18       Impact factor: 12.701

8.  Presumed primary malignant melanoma of the liver: a case report.

Authors:  Kotaro Shibagaki; Hiraku Fujita; Reijiro Maejima; Yasushi Ishii; Masahiro Oishi; Ken Seshimo; Masahito Kodera; Yutaka Yamashita; Yutaka Masuji; Keita Kobayashi; Yoshikazu Kinoshita
Journal:  Clin J Gastroenterol       Date:  2008-06-07

Review 9.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

10.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.